Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Genotype 1 hepatitis C virus (HCV) patients who did not respond (did not lose virus during
treatment) or relapsed (virus went away on treatment but came back after treatment was
stopped) after treatment with at least twelve weeks of a pegylated (long-acting) interferon
and ribavirin will be considered for this study. There are two purposes to this study: first,
to determine how rosiglitazone, a medicine used to treat diabetes, affects the HCV viral
load; and second, to determine if treatment of insulin resistance with rosiglitazone prior to
therapy for HCV will improve sustained virologic response (loss of virus that continues
beyond six months after completion of HCV therapy) to HCV therapy.